bluuebunny/crossref_metadata_2025_split huggingface dataset:
P0479 The impact of inflammatory bowel disease on sexuality of male and female patients
Authors: Szymanska E , Kisielewska L , kotkowicz-szczur M , Kisielewski R , Jaroslaw K 
Published: January 2025

Abstract

Background
Inflammatory bowel disease (IBD) is a chronic condition that globally affects the health of individuals who suffer from it, deteriorating their quality of life (QoL), which includes one’s sexual functioning. The aim of this study was to assess the influence of intestinal disease on sexuality of male and female with IBD.

Methods: Patients and Methods
A prospective survey study on male and female individuals with IBD using an anonymous questionnaire including 60 inquiries concerning patients ‘intimate relationship and sexual functioning was performed. The following statistical tests were used: chi-square test of independence, Spearman’s rank correlation coefficient, Wilcoxon and U Mann-Whitneyatests. The significance level of p = 0.05 was assumed as statistically significant.

Results
The survey included 110 respondents with IBD (41% with Crohn’s disease and 57% with ulcerative colitis) - 52 women (47%) and 58 men (53%). Most of them were aged between 31 and 40 (45%).
Statistically significant differences were found in the assessment of satisfaction with sex after IBD diagnosis between the groups - female vs male (p = 0.041). Women gave different ratings on a 5-point scale, most often 1 (23%), 4 (23%) and 5 (27%), while men most often gave 4 (49%) and 5 (26%). Despite the disease, men were more likely than women not to give up sexual activity: 53% vs 43%, respectively (p = 0.011). While women were more likely than men to be afraid that after being diagnosed with IBD they would be less attractive to their partner: 31% vs 10%, respectively (p = 0.002). Nearly 31% of women after diagnosis of IBD did not have orgasm or achieved it less frequently than before the diagnosis, which was less common in men (4%). The difference was statistically significant (p = 0.002). Men more often than women did not change their erotic perception of the partner after IBD diagnosis: 71% vs 39%. The difference was statistically significant (p = 0.001). Women (70%) were more likely than man (28%) to expect a gastroenterologist to inform about sexuality and fertility in IBD. The difference was statistically significant (p &lt; 0.001).

Conclusion
According to our survey IBD has more negative impact on sexuality of female patients. After the diagnosis women were less satisfied with sex, felt less attractive to their partner and more often resigned from sexual intercourse because of the disease. However, women were more interested in information about sexuality and fertility in IBD than men.
P0481 Real-World Analysis of Disease Progression in Ulcerative Colitis: A Comparative Study Across Diagnostic Eras at a Tertiary IBD Center
Authors: Valdivia Krag C , Mirabent C , González Castilla M L , Benítez J M , Marín Pedrosa S , Soto P , Iglesias-Flores E , Gros B 
Published: January 2025

Abstract

Background
Ulcerative colitis (UC) is a chronic condition characterized by a relapsing-remitting course, leading to cumulative systemic damage and disease progression. This progression may include extension of colitis, new extraintestinal manifestations (EIMs), dysplasia/colorectal cancer (CRC), and the need for colectomy. This study aimed to compare disease progression based on the time of diagnosis, to assess the impact of new therapeutic options.

Methods
Retrospective study at Reina Sofía University Hospital, analyzing all UC patients diagnosed within the past 10 years (2014-2023, cohort B) and a matched cohort diagnosed prior to 2014 (cohort A). Disease progression was defined as the first occurrence of new EIMs, new dysplasia/CRC, need for colectomy, or progression of UC extension. Kaplan-Meier analysis was used to calculate time to progression events.

Results
Of 643 patients identified, 72 were excluded, leaving 571 for analysis. Among them, 194 (34%) were diagnosed before 2014 and 377(66%) within the last decade (2014-2023). Median age at diagnosis was 39.5 years (IQR 27.3–54.2), and 304 (53.2%) were male. Initial disease extent was: proctitis 147(25.7%), left-sided colitis 203 (35.6%) and pancolitis 191 (33.5%). At diagnosis, 40 (7%) had EIMs.
During a median follow-up of 7.1 years (3.7–13.3), 223(39.1%) patients experienced disease progression, including extension of colitis in 57(10%) cases, new EIMs in 114 (20%), colectomy in 46 (8.1%), and dysplasia/CRC in 56(9.8%). Patients diagnosed within the last decade showed a shorter time to progression compared to those diagnosed prior to 2014 (log-rank test, p&lt;0.0001). This trend was also observed for new EIMs (p=0.01), dysplasia/CRC (p&lt;0.0001), and disease extension (p=0.014) (Figure 1B-E). However, no significant difference was found in time to colectomy between groups (p=0.31) (Figure 1F).
First maintenance therapy was mesalazine in 366(97.9%) of patients diagnosed within the last decade compared to those diagnosed previously 178(96.7%). Corticosteroids were used at some point in 379(69.4%), median number of corticosteroid courses of 2(1-4). Advanced therapy during follow-up was prescribed in 94(24.9%) of patients diagnosed in the last decade compared to 66(34%) of those diagnosed previously, p=0.022. However, time to advanced therapy prescription was significantly shorter in patients with recent diagnosis (log-rank test p=0.014) (Figure 1A)

Conclusion
A substantial proportion of patients with UC experienced disease progression within a follow-up period of less than 10 years. Despite the availability and earlier use of advanced therapeutic options, disease progression was observed to occur sooner in patients diagnosed within the last decade, compared to those diagnosed before 2014.
P0482 Diagnostic yield of Small Bowel Capsule endoscopy and Double Balloon Enteroscopy for Small bowel Crohn’s disease
Authors: Sheehan T , Clarke M , Deane C , Kelly O , Hall B 
Published: January 2025

Abstract

Background
Small Bowel Capsule Endoscopy (SBCE) a valuable tool in visualizing the small bowel (SB) SBCE paired with Double Balloon Enteroscopy (DBE) can obtain histology to investigate Crohn’s disease (CD). Diagnostic yield was assessed using SBCE & DBE.

Methods
A retrospective analysis of patients referred to SBCE service with suspected CD. PillCam SB3 was used in this study with one reporting gastroenterologist. Previous colonoscopy, histology, faecal calprotectin (FC) & MR enterography (MRE) analysed. Linear regression statistical analysis performed.

Results
94 patients (50% female, median age = 44). No prior diagnosis of CD. 99% completed study rate.
Pre-referral, 46 had Colonoscopy, 26 elevated FC (median = 160) & 8 had abnormal MRE. Abnormal MRE findings: mural thickening of SB, strictures and terminal ileitis. Raised FC was not statistically significant for a SBCE finding in keeping with CD p = 0.357 however, an abnormal MRE was p=0.034.
64.8% of SBCE had an abnormal report, 35.1% had findings in keeping with CD i.e. 54% of abnormal findings on SBCE were indicative of CD. Further investigations: repeat SBCE (10.7%), repeat ileocolonoscopy (1.96%) RDBE (16.6%) & ADBE (10.7%). Repeat SBCE was performed to assess healing. No further diagnosis of CD made with DBE.

Conclusion
SBCE and DBE are useful adjunct diagnostic tools rather than the primary investigations. A positive yield on SBCE did not correlate to diagnosis of CD. FC did not show significant correlation to a positive diagnosis. MRE showed to be significant precursor to SBCE. Similar research including intestinal ultrasound should be conducted.
P0485 Seroproteomic index of endoscopic activity associates with endoscopic outcomes in a longitudinal cohort of adults ulcerative colitis
Authors: Boland B , Zablan K , Penrose H , Neill J , Le H , Ho J , Dervieux T 
Published: January 2025

Abstract

Background
A seroproteomic index of endoscopic activity (serum index) is validated in adult CD but its performance in Ulcerative Colitis (UC) is lacking. We prospectively evaluated the serum index in an observational cohort of adult UC undergoing longitudinal endoscopic assessments.

Methods
UC underwent Montreal classification, were consented and followed longitudinally for their outcomes (clinical and endoscopic) at a single center. Serum specimens were collected at the time of assessments. The UC endoscopic index score (UCEIS) was calculated, with scores above 4 points indicating endoscopic active disease. Clinical symptoms were measured using the partial Mayo score with score &lt; 2 points indicating clinical remission. The serum index which is a composite of CRP-HS plus 12 other proteins in an algorithm that associates with endoscopic outcomes in CD was applied unmodified in UC. The index ranges from 0 to 100 points where higher index are associated with higher likelihood of endoscopic active disease. All sera were processed by an accredited clinical laboratory. Receiver operating characteristic curves (ROC with area under the curve [AUC]) and logistic regression were employed to evaluate the index in distinguishing endoscopic outcomes. Nonlinear mixed effect models were used to correlate the longitudinal changes in UCEIS (&gt;1 endoscopic assessment).

Results
A total of 231 patients with UC (mean age 41 years, n=115 females) were enrolled, and 294 serum samples with an UCEIS score were collected. Average partial Mayo score was 2.5±2.7 points [SD] with 50% assessments in clinical remission. Average UCEIS was 2.2±2.3 points (22% [n=66] with UCEIS&gt;4 points). Average CRP, and serum index was 5.2±8.1 mg/L, and 38±19 points, respectively. Comparison in distinguishing UCEIS&gt;4 points yielded significantly higher AUC with serum index (AUC=0.797±0.034) than with CRP (AUC=0.714±0.035) (p=0.047). In subjects with more than one endoscopic assessment (n=49/112 endoscopies), the change in partial Mayo scores, CRP and serum index associated with the changes in the UCEIS (Table).
At optimal cutoff, serum index above 42 points yielded 73% sensitivity and 78% specificity in identifying moderate to severe endoscopic disease (OR= 9.0 95%CI: 5.0-17.2) (p&lt;0.001) (PPV=52%, NPV=89% with 25% pretest probability). In multivariate analysis, endoscopic active disease associated with the absence of clinical remission (aOR=0.05 (95%CI: 0.01,0.16) with each point increase in serum index yielding 1.05 (95%CI: 1.03,1.07) fold higher likelihood of endoscopic active disease (Figure).

Conclusion
We have validated the performance of a seroproteomic index of endoscopic activity in adults with UC demonstrating its potential as a non-invasive biomarker.
P0487 Understanding the learning curve of intestinal ultrasound in IBD: a comparative study between novice, regular and expert
Authors: Bove L , Meyer J , Collins M , Frampas E , Bourreille A , Le Berre C 
Published: January 2025

Abstract

Background
Intestinal ultrasound (IUS) has emerged as a valuable tool for monitoring inflammatory bowel disease (IBD), but its reliability depends on the technical skills of the operator. This study aimed to assess the IUS learning curve of a complete novice and a gastroenterologist with formal general ultrasound training and regular IUS experience, using an expert radiologist as the gold standard.

Methods
This was a single-center, prospective study conducted between April 2023 and January 2024, which consecutively included patients with IBD (Crohn’s disease [CD], ulcerative colitis [UC]). Three IUS scans were performed successively and in a standardized manner by the three operators in each included patient. Each operator assessed disease activity using quantitative and semi-quantitative scales, and ultrasound activity scores based on bowel wall thickness and stratification, Doppler signal intensity according to the Limberg score, and appearance of mesenteric fat. Inter-operator agreement was calculated using the intraclass correlation coefficient (ICC).

Results
A total of 50 patients were included (76.6% CD; 23.4% UC), of whom 31.9% had active disease and 23.4% a history of IBD-related surgery. Mean BMI (standard deviation [SD]) was 24.2 (4.2) kg/m². Mean examination time was 4’12’’ for the expert radiologist (gold standard), 3’45’’ for the experienced gastroenterologist, and 5’17’’ for the novice (p&lt;0.001). Regarding quantitative assessment of IUS activity (visual analog scale), the experienced gastroenterologist had good agreement with the radiologist throughout the study (ICC ranging from 0.61 at the start of the study to 0.79 at the end; overall ICC = 0.71 [95% CI 0.54-0.83]), while the novice maintained poor agreement, with no learning curve (ICC increasing from 0.21 to 0.33; overall ICC = 0.33 [0.05-0.55]). Similar results were obtained with the other activity measurements. The ileocolonic location of CD and surgical history significantly impaired novice performance. Excluding surgical patients enabled a learning curve to be obtained for the novice, with poor initial agreement (ICC 0.21) then moderate to good agreement at the end of the study (ICC 0.59).

Conclusion
A formal general ultrasound training and 200 IUS examinations of experience allowed good agreement with an expert radiologist in IBD patients. The novice failed to go beyond poor agreement throughout the study, although a faster learning curve was observed in patients without history of IBD surgery. These findings highlight the difficulty of the technical performance of IUS rather than its interpretation. Comprehensive training beforehand and between 50 and 200 examinations of experience are necessary before embarking on IUS.
P0489 The impact of inflammatory bowel disease and disease activity on patients’ sexuality
Authors: Szymanska E , Kisielewska L , Kotkowicz-Szczur M , Kisielewski R , Kierkus J 
Published: January 2025

Abstract

Background
Sexuality is an integral part of general health and wellbeing. Chronic diseases, such as inflammatory bowel disease (IBD), have an impact on patients’ sexual functioning. The aim of this study was to assess the influence of intestinal disease and its activity on sexuality of individuals with IBD.

Methods: Patients and Methods
A prospective survey study on male and female individuals with IBD using an anonymous questionnaire including 60 inquiries concerning patients ‘intimate relationship and sexual functioning was performed. The following statistical tests were used: chi-square test of independence, Spearman’s rank correlation coefficient, Wilcoxon and U Mann-Whitneyatests. The significance level of p = 0.05 was assumed as statistically significant.

Results
The survey involved 110 respondents with IBD (41% with Crohn’s disease and 57% with ulcerative colitis) - 52 women (47%) and 58 men (53%). Most of them were aged between 31 and 40 (45%).
Before being diagnosed with IBD, the respondents rated their satisfaction with sex on an average of 4.1 on a 5-point scale; after the diagnosis, the rating was lower and amounted to 3.6. In 34% of respondents, the assessment of satisfaction with sex after diagnosis decreased, in 24% it increased, and in 42% it did not change. The difference between the assessments before and after diagnosis was statistically significant (p = 0.007).
Statistically significant correlations were found between IBD clinical activity and the impact of the disease on the sexual desire (p &lt; 0.001), the need for sex after diagnosis (p &lt; 0.001), satisfaction with sex after diagnosis (p = 0.003), and the average number of intercourse (p = 0.004), average duration of intercourse after diagnosis (p = 0.001), feeling guilty in the sexual sphere due to the disease (p = 0.006), assessment of one’s attractiveness since diagnosis (p = 0.032), and change in the partner’s erotic perception after diagnosis ( p &lt; 0.001). Respondents with disease exacerbation were less willing to engage in sexual activity, had less need for intercourse, rated their satisfaction with sex lower, had fewer intercourse, and their duration was shorter. They more often felt sexual guilt due to the disease and assessed their current attractiveness worse.

Conclusion
Inflammatory bowel disease has negative impact on patents’ sexuality and disease activity strongly affects their sexual functioning. The exacerbation of IBD causes in patients decrease in sexual needs, worse sexual experience and lower assessment of one’s attractiveness.
P0490 Diagnosis and treatement of latent tuberculosis infection in patients with chronic Inflammatory Bowel Disease candidates for anti-TNFα therapy in a tuberculosis endemic country
Authors: Mouslim I , jioua C , touibi A , ouahid S , nejjari F , berrag S , Tarik A , Mouna T 
Published: January 2025

Abstract

Background
The increasing use of anti-TNFα agents in the management of IBD raises concerns about the increased risk of latent TB reactivation, justifying the need for effective screening recommendations.
Our study focuses on IBD patients candidates for anti-TNF therapy aiming to determine the prevalence of latent TB infection, examine factors influencing QantiFERON® outcomes, and describe therapeutic modalities for latent TB in this population.

Methods
This was a descriptive retrospective study of 87 patients followed up in the gastroenterology department of the Mohammed V Military Training Hospital in Rabat for IBD who were candidates for anti-TNF alpha biotherapy between 2021 and 2024.

Results
The prevalence of latent tuberculosis TBL identified in patients with chronic inflammatory bowel disease candidates for anti-TNFα therapy in our study was 24.1%, detected by the Quantiferon Gold IT® test. Factors influencing the results of the test found mainly include the various risk factors for tuberculosis in our context of intermediate endemicity, and the use of immunosuppressants, which is associated with a negative test. As the intradermal tuberculin test could not be carried out in Morocco due to a stock shortage, the comparison of the performance of the two tests was not possible. Despite an initially negative Quantiferon Gold IT® test, 4 cases of active tuberculosis were recorded after initiation of anti-TNF treatment.

Conclusion
The IGRA Quantiferon Gold IT® test is considered a valuable tool for detecting latent tuberculosis in IBD patients who are candidates for anti-TNF treatment. However, its use and interpretation in an endemic country and in vaccinated subjects should be the subject of larger-scale studies aimed at proposing appropriate recommendations based on the risk of latent tuberculosis.
P0495 Impact of the HLA DQA1*05 allele on the efficacy of vedolizumab treatment in inflammatory bowel disease
Authors: Castro Torres S , Ramiro cuenca L , Rodríguez-Moranta F , Rodríguez-Alonso L , Ruiz-Cerulla A , Sánchez-Pastor E , Antón-Güell S , Guardiola Capon J 
Published: January 2025

Abstract

Background
Patients with inflammatory bowel disease (IBD) carrying the HLA-DQA1*05 allele have a higher risk of developing immunogenicity and loss of response to anti-TNFs. On the other hand, this association has not been observed with ustekinumab, a fact that could help individualize treatment (J. Guardiola ECCO 2024). We do not have data for vedolizumab.

Methods: Objective
To evaluate the relationship between the HLA-QA1*05 allele and the loss of response and the persistence of treatment with vedolizumab.

Methods
Design: Unicentric retrospective cohort study from a tertiary hospital.

Population
IBD patients who have completed induction with vedolizumab.

Loss of response
need for intensification, change of treatment, hospitalization or surgery.

Analysis
univariate (Kaplan Meyer) and multivariate (Cox Regression) analyses.

Results
We included 67 patients with IBD (24 Crohn’s disease and 43 ulcerative colitis) with an average follow-up of 29±21 months. Both cohorts were comparable in relation to baseline characteristics. 44% were carriers of the risk allele. 74% had previous exposure to biologicals. Mean basal and postinduction calprotectin were 866±1103 and 295±1228, respectively. 28 (46%) of the patients lost response during follow-up. During this period 29%, 25%, 7% and 42% required hospitalization, treatment with corticosteroids, surgery or intensification respectively.
We found no differences in relation to clinical or biological remission rates at 6 and 12 months, nor differences in discontinuation rates in relation to the status of carriers of the risk allele. The mean duration free of loss of response was 28 months (95% CI: 9-46) in individuals not carrying the HLA-DQA1*05 allele and 13 months (95% CI: 9-16) in those carriers, without significant differences between both groups (Log Rank p=0.517) (Figure 1).
In multivariate analysis, after adjusting for treatment with prior biologics, obesity and type of IBD, the presence of the HLA-DQA1*05 allele was not associated with loss of response to vedolizumab or persistence of the treatment.

Conclusion
The presence of the HLA-DQA1*05 allele is not associated with loss of response or persistence of vedolizumab treatment.
P0499 A multicenter study utilizes multi-scale clinical data from Crohn’s disease patients to develop large-scale language-human interaction models for predicting the progression of intestinal diseases
Authors: Li Z , Zhang R , Wang Y , Wang X , Mao R , Feng S T , Li X 
Published: January 2025

Abstract

Background
The hospital admission records of patient with Crohn’s disease (CD) contain extensive textual content that provides a valuable resource for gaining a thorough understanding of the disease development and progression. The medical application of large language model (LLM) has been extensively researched. We aim to employ LLMs to analyze multi-scale clinical data from patients with CD and predict their gastrointestinal outcomes.

Methods
By analyzing the clinical data and relevant literature, we established a comprehensive database incorporating intestinal disease related factors while selecting three highly representative LLMs (ChatGPT-4omini, ChatGPT-4o, and Gemini-Pro) through prompt engineering of original LLMs with chain-of-thought, knowledge-guided prompting, and self question. Nine combined models were then developed and their performances to predict the intestinal disease were compared. The comprehensiveness, accuracy, conciseness, and readability of logicality reports generated by different LLMs were evaluated.

Results
The clinical data of 649 patients from six clinical centers were retrospectively collected. Following two rounds of evaluation by ten experts in CD diagnosis and treatment, a total of 117 disease related factors out of 199 were selected to construct the LLM prompt. The ChatGPT-4o’s level-3 model demonstrated superior predictive performance in predicting intestinal outcomes for patients within center-1 as training set, achieving an accuracy of 0.844, sensitivity of 1.000, and specificity with 0.783 (ChatGPT4o-mini: 0.688, 1.000, 0.665; Gemini-pro: 0.758, 1.000, 0.708). For patients from other five medical centers as testing set, the accuracy reached a value at 0.835 (sensitivity: 1.000, specificity: 0.768). However, the readability tests indicate that Gemini-pro offers a better comprehensiveness than others.

Conclusion
The ChatGPT-4o human-computer interaction model based on multi-scale clinical data of CD patients can accurately predict the progression of intestinal diseases, providing accurate and effective basis for precise management of Crohn’s disease in clinical practice. The Gemini-pro offers a more comprehensible method for non-clinical-experts to under their condition of intestinal disease.